Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowPatients on Eli Lilly and Co.’s experimental diabetes pill lost more weight and had better blood sugar control than those on an older, approved rival from Novo Nordisk A/S in the first head-to-head trial of the two medicines.
The highest dose of Lilly’s pill—called orforglipron—led to a 1.9% drop in blood sugar levels, compared with a 1.5% reduction with Novo’s drug Rybelsus, Lilly said in a statement on Wednesday. Patients given orforglipron lost 8.2% of their body weight—roughly 18 pounds—in 52 weeks, while those on Novo’s drug lost 5.3% of their body weight—about 12 pounds.
Lilly shares were up 0.57% by midday Wednesday.
Lilly also released the first full look at how orforglipron helped patients with obesity this week and is presenting that data at the European Association for the Study of Diabetes meeting in Vienna Wednesday.
The medicine, plus a more potent, experimental version of Novo’s GLP-1 pill, are expected to help drive the future of the diabetes and weight-loss drugs that have captivated the public.
Doctors at the meeting welcomed the results, saying the tablet will make it possible to treat more patients because it’s easier to produce and to take, and may eventually be cheaper. Lilly officials pledged to get the medicine to market as quickly as possible.
“It’s probably one of the most important medicines we’ve ever launched from a global health perspective,” Lilly Chief Scientific Officer Dan Skovronsky said in an interview with Bloomberg TV. “We’ll do everything we can to make sure that the burden on patients is as low as possible in every way possible, including economic burden for patients.”
Lilly and Novo have been locked in a fierce battle to control the obesity market, which is projected to reach $100 billion by the end of the decade, according to Bloomberg Intelligence. Both companies have highly effective shots on the market, but pills are seen as the key to reaching more patients.
The latest study funded by Lilly was designed to compare how well the two pills controlled blood sugar in patients with diabetes, but it also looked at weight loss. It enrolled about 1,700 patients whose blood sugar levels were not adequately controlled with metformin, a common diabetes treatment.
Side effects in the study were mostly stomach-related. More patients stopped taking Lilly’s pill due to side effects than Novo’s, though Lilly cautioned the study was not powered to compare the two drugs’ tolerability.
“These results, combined with orforglipron’s once-daily oral dosing and broad scalability, reinforce its potential as a foundational treatment for Type 2 diabetes,” Kenneth Custer, executive vice president Lilly Cardiometabolic Health, said in a statement.
Lilly plans to ask regulators to approve the drug as a diabetes treatment in 2026, according to a statement.
In the meantime, Lilly is moving quickly to get its pill approved as a treatment for obesity, which is seen as a more lucrative market. It expects regulators to make a decision on whether or not to approve the treatment for weight loss early next year.
Both pills are taken daily, but there are some key differences between the two. Novo’s pill has some restrictions around food and water intake, while Lilly’s does not. Orforglipron is also a small molecule drug, meaning it’s relatively easy to manufacture compared to shots. Novo’s pill, on the other hand, is a peptide made from the same ingredient as its best-selling drugs Ozempic and Wegovy, semaglutide.
Please enable JavaScript to view this content.
Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our comment policy that will govern how comments are moderated.